Palmitoylethanolamide
18 benefits mapped to clinical evidence across supplements.
Dose per serving from products
60 products in our catalogue print how much Palmitoylethanolamide a serving holds.
Most common: 500 mg to 1 g, 45% of 60 products.
| Dose per serving | Products |
|---|---|
| 25 mg or less | 1 |
| 25 mg to 50 mg | 5 |
| 50 mg to 100 mg | 5 |
| 100 mg to 250 mg | 6 |
| 250 mg to 500 mg | 16 |
| 500 mg to 1 g | 27 |
Dose per serving from research
31 study groups in 26 studies say how much Palmitoylethanolamide participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 500 mg to 1 g, 55% of 31 study groups.
| Daily dose | Study groups |
|---|---|
| 250 mg to 500 mg | 4 |
| 500 mg to 1 g | 17 |
| 1 g to 2.5 g | 10 |
Commonly used together
15 of 31 study groups took Palmitoylethanolamide with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Luteolin | 8 |
Benefit Evidence
Inflammation/itch ↓; hydration ↑
Pain/resolution improved: +98%/96%
URTI episodes ↓: 39 vs 64
Pain relief / sleep
Nerve conduction +≈33%
Inflammation down, cytokines↓
Stress resilience +faster symptom relief
Stress resilience -inflammation -11.5
Fatigue/cognition: GABAB + plasticity
Pain/inflammation: reduced pain, IL-6
Inflammation/itch ↓; hydration ↑
Pain/resolution improved: +98%/96%
URTI episodes ↓: 39 vs 64
Stress resilience +faster symptom relief
Stress resilience -inflammation -11.5
Research sources
Pain relief (13)
- Effectiveness of the Association N-Palmitoylethanolamine and Transpolydatin in the Treatment of Primary Dysmenorrhea
PubMed ID: 26233289
Large RCT: oral PEA+transpolydatin markedly reduced primary dysmenorrhea pain vs placebo.
- Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome
PubMed ID: 28164346
Randomized DB trial: PEA/polydatin reduced abdominal pain in IBS patients vs placebo.
- Efficacy of ultramicronized palmitoylethanolamide in burning mouth syndrome-affected patients: a preliminary randomized double-blind controlled trial
PubMed ID: 30361792
Small RCT: ultramicronized PEA reduced burning‑mouth intensity vs placebo.
- A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis
PubMed ID: 30927159
Dose‑related, double‑blind RCT showed clear reductions in pain and WOMAC scores in knee OA.
- A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain
PubMed ID: 36057884
Quadruple‑blind RCT produced large clinically meaningful reductions in diabetic neuropathic pain and interference.
- Efficacy of Topical Palmitoylethanolamide (Levagen+) for the Management of Eczema Symptoms: A Double-Blind, Comparator-Controlled, Randomized Clinical Trial
PubMed ID: 38408443
Topical PEA reduced eczema severity and itch vs comparator, decreasing discomfort.
- Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial
PubMed ID: 37380908
Large trial of PEA‑LUT + training reduced olfactory symptoms (parosmia/hyposmia), lowering discomfort.
- Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo- Controlled Clinical Trial
PubMed ID: 35450527
Reducing parosmia and improving smell function reduces sensory discomfort (large RCT).
- Palmitoylethanolamide and acetyl-L-carnitine act synergistically with duloxetine and pregabalin in fibromyalgia: results of a randomised controlled study
PubMed ID: 37378482
Add‑on PEA+ALC produced significant reductions in fibromyalgia pain/function scores in an RCT.
- The efficacy of an association of palmitoylethanolamide and alpha-lipoic acid in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized clinical trial
PubMed ID: 28403589
Randomized single‑blind trial: PEA+ALA improved chronic prostatitis symptom scores vs active comparator.
- Ultra-micronized Palmitoylethanolamide Effects on Sleep-wake Rhythm and Neuropathic Pain Phenotypes in Patients with Carpal Tunnel Syndrome: An Open-label, Randomized Controlled Study
PubMed ID: 29676237
Ultramicronized PEA produced large reductions in neuropathic pain in carpal tunnel patients.
- A randomized interventional clinical trial assessing the safety and effectiveness of PeaNoc XL tablets in managing joint pain and inflammation in arthritis patients
PubMed ID: 37767025
PEA+astaxanthin as an add‑on reduced pain (WOMAC) and inflammatory markers in arthritis patients.
- Efficacy and Safety of the Combination of Palmitoylethanolamide, Superoxide Dismutase, Alpha Lipoic Acid, Vitamins B12, B1, B6, E, Mg, Zn and Nicotinamide for 6 Months in People with Diabetic Neuropathy
PubMed ID: 39339645
Combination supplement including PEA reduced neuropathic pain (attribution to PEA uncertain but effect present).
Wellbeing (11)
- Palmitoylethanolamide and acetyl-L-carnitine act synergistically with duloxetine and pregabalin in fibromyalgia: results of a randomised controlled study
PubMed ID: 37378482
Fibromyalgia composite score improvements (FIQR, WPI) reflect gains in overall quality of life/wellbeing.
- Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial
PubMed ID: 29486338
Strong RCT evidence of improved depression symptoms with adjunctive PEA—clear positive impact on overall wellbeing.
- A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis
PubMed ID: 30927159
Knee OA trial yielded meaningful pain and function benefits that improve overall wellbeing.
- Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram
PubMed ID: 32591562
Objective visual function and QoL gains in glaucoma patients indicate improved overall wellbeing.
- A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain
PubMed ID: 36057884
Robust RCT showing large pain, function, sleep and mood benefits—substantial overall wellbeing impact.
- Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo- Controlled Clinical Trial
PubMed ID: 35450527
Multicenter RCT improving olfaction and related quality‑of‑life outcomes.
- A randomized interventional clinical trial assessing the safety and effectiveness of PeaNoc XL tablets in managing joint pain and inflammation in arthritis patients
PubMed ID: 37767025
Pain, inflammation and function improvements in arthritis patients would support overall wellbeing gains.
- Efficacy of Topical Palmitoylethanolamide (Levagen+) for the Management of Eczema Symptoms: A Double-Blind, Comparator-Controlled, Randomized Clinical Trial
PubMed ID: 38408443
Topical PEA improved eczema symptoms and POEM scores—better skin‑related wellbeing.
- Targeting PTSD with ultramicronized palmitoylethanolamide: Results from a randomized trial integrating pharmacotherapy and cognitive behavioral therapy
PubMed ID: 41240672
Large and sustained reductions in PTSD/anxiety symptoms with ultramicronized PEA (±CBT) imply improved overall wellbeing.
- Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial
PubMed ID: 37380908
Large olfactory recovery trial markedly improving smell function, which strongly affects quality of life.
- The Efficacy of Palmitoylethanolamide (Levagen+) on the Incidence and Symptoms of Upper Respiratory Tract Infection-A Double Blind, Randomised, Placebo-Controlled Trial
PubMed ID: 37892528
Fewer URTIs and milder symptoms over 12 weeks contribute to better general wellbeing.
Daily comfort (10)
- The efficacy of an association of palmitoylethanolamide and alpha-lipoic acid in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized clinical trial
PubMed ID: 28403589
Improved prostatitis and urinary symptom scores after 12 weeks of PEA+ALA translate into better daily comfort.
- Effectiveness of the Association N-Palmitoylethanolamine and Transpolydatin in the Treatment of Primary Dysmenorrhea
PubMed ID: 26233289
High responder rate for dysmenorrhea indicates markedly greater daily comfort during menses.
- A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain
PubMed ID: 36057884
DPN RCT improved pain, sleep and mood, yielding broad daily comfort gains.
- Efficacy of Topical Palmitoylethanolamide (Levagen+) for the Management of Eczema Symptoms: A Double-Blind, Comparator-Controlled, Randomized Clinical Trial
PubMed ID: 38408443
Topical PEA cream reduced eczema severity and itch, improving day‑to‑day skin comfort.
- The Efficacy of Palmitoylethanolamide (Levagen+) on the Incidence and Symptoms of Upper Respiratory Tract Infection-A Double Blind, Randomised, Placebo-Controlled Trial
PubMed ID: 37892528
Fewer URTI episodes and milder cough/throat symptoms increased general daily wellbeing across 12 weeks.
- A randomized interventional clinical trial assessing the safety and effectiveness of PeaNoc XL tablets in managing joint pain and inflammation in arthritis patients
PubMed ID: 37767025
Arthritis patients experienced less pain and improved function, likely increasing day‑to‑day comfort.
- Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram
PubMed ID: 32591562
Glaucoma trial showed improved PERG, lower IOP and a meaningful NEI‑VFQ quality‑of‑life increase (daily comfort/vision).
- A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis
PubMed ID: 30927159
Knee OA RCT reduced pain and improved function (directly increases daily comfort).
- Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome
PubMed ID: 28164346
PEA/polydatin reduced IBS abdominal pain—improves daily comfort for sufferers.
- Palmitoylethanolamide and acetyl-L-carnitine act synergistically with duloxetine and pregabalin in fibromyalgia: results of a randomised controlled study
PubMed ID: 37378482
Significant improvements in fibromyalgia impact (FIQR) with PEA+ALC imply greater day‑to‑day comfort/function.
Inflammation (7)
- Palmitoylethanolamide and polydatin in pediatric irritable bowel syndrome: A multicentric randomized controlled trial
PubMed ID: 38479039
Pediatric co‑micronized PEA+polydatin increased complete remission rates and reduced pain/frequency in IBS, lowering relapse/flare risk.
- Persistent COVID-19 parosmia and olfactory loss post olfactory training: randomized clinical trial comparing central and peripheral-acting therapeutics
PubMed ID: 38492007
umPEALUT ± ALA trials produced high parosmia resolution rates—fewer symptomatic flare‑ups of parosmia in persistent post‑COVID cases.
- Efficacy of Topical Palmitoylethanolamide (Levagen+) for the Management of Eczema Symptoms: A Double-Blind, Comparator-Controlled, Randomized Clinical Trial
PubMed ID: 38408443
Topical PEA reduced eczema severity over 4 weeks, consistent with fewer/less intense flares.
- Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome
PubMed ID: 28164346
IBS abdominal pain reduction suggests potential for fewer symptomatic flares though mucosal markers unchanged.
- Effectiveness of the Association N-Palmitoylethanolamine and Transpolydatin in the Treatment of Primary Dysmenorrhea
PubMed ID: 26233289
Per‑cycle oral PEA+transpolydatin markedly reduced dysmenorrhea pain—strong evidence for fewer cyclical flare‑ups.
- N-palmitoylethanolamine and N-acetylethanolamine are effective in asteatotic eczema: results of a randomized, double-blind, controlled study in 60 patients
PubMed ID: 25071367
Topical PEA/AEA improved eczema itch and sensory threshold quickly—may reduce frequency/severity of symptom flares.
- The Efficacy of Palmitoylethanolamide (Levagen+) on the Incidence and Symptoms of Upper Respiratory Tract Infection-A Double Blind, Randomised, Placebo-Controlled Trial
PubMed ID: 37892528
Large RCT showed significantly fewer URTI episodes and fewer participants ill at least once with daily PEA.
Muscle soreness (5)
- A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis
PubMed ID: 30927159
Large OA RCT reduced pain and worst/least NRS values—translates to less soreness during daily activities.
- Palmitoylethanolamide and acetyl-L-carnitine act synergistically with duloxetine and pregabalin in fibromyalgia: results of a randomised controlled study
PubMed ID: 37378482
Fibromyalgia add‑on trial reduced pain scores (WPI/FIQR), consistent with less soreness.
- Effectiveness of the Association N-Palmitoylethanolamine and Transpolydatin in the Treatment of Primary Dysmenorrhea
PubMed ID: 26233289
Large RCT: PEA+transpolydatin markedly improved dysmenorrhea pain (less soreness/cramping) vs placebo.
- A randomized interventional clinical trial assessing the safety and effectiveness of PeaNoc XL tablets in managing joint pain and inflammation in arthritis patients
PubMed ID: 37767025
Arthritis cohort reported reduced pain (WOMAC) which would include soreness reduction.
- Efficacy and Safety of the Combination of Palmitoylethanolamide, Superoxide Dismutase, Alpha Lipoic Acid, Vitamins B12, B1, B6, E, Mg, Zn and Nicotinamide for 6 Months in People with Diabetic Neuropathy
PubMed ID: 39339645
Combination supplement including PEA reduced neuropathic pain and related discomfort (indirect attribution).
Nerve health (5)
- Palmitoylethanolamide and acetyl-L-carnitine act synergistically with duloxetine and pregabalin in fibromyalgia: results of a randomised controlled study
PubMed ID: 37378482
Fibromyalgia pain improvements with PEA+ALC likely reflect relief of neuropathic/distributed nociceptive symptoms.
- Efficacy of ultramicronized palmitoylethanolamide in burning mouth syndrome-affected patients: a preliminary randomized double-blind controlled trial
PubMed ID: 30361792
Ultramicronized PEA reduced burning‑mouth symptoms (neuropathic oral pain) in a randomized trial.
- A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain
PubMed ID: 36057884
High‑quality RCT showing large reductions in diabetic peripheral neuropathic pain and interference with good biomarker support.
- Efficacy and Safety of the Combination of Palmitoylethanolamide, Superoxide Dismutase, Alpha Lipoic Acid, Vitamins B12, B1, B6, E, Mg, Zn and Nicotinamide for 6 Months in People with Diabetic Neuropathy
PubMed ID: 39339645
Six‑month combo (including PEA) significantly reduced neuropathic pain and modestly improved nerve‑function measures.
- Ultra-micronized Palmitoylethanolamide Effects on Sleep-wake Rhythm and Neuropathic Pain Phenotypes in Patients with Carpal Tunnel Syndrome: An Open-label, Randomized Controlled Study
PubMed ID: 29676237
Ultramicronized PEA notably reduced neuropathic pain in carpal tunnel patients awaiting surgery.
Mood balance (5)
- A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain
PubMed ID: 36057884
DPN trial documented mood improvement as a secondary outcome alongside pain/function gains.
- Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial
PubMed ID: 29807317
Adjunctive PEA with risperidone improved irritability/hyperactivity in children with autism—clinically meaningful behavioral/mood benefit.
- Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial
PubMed ID: 29486338
Randomized DB add‑on: PEA with citalopram produced faster and larger reductions in HAM‑D and higher response rates.
- Efficacy and safety of palmitoylethanolamide as an adjunctive treatment for acute mania: A randomized, double-blind, placebo-controlled trial
PubMed ID: 35737597
Adjunctive PEA added to mood‑stabilizing/antipsychotic regimen reduced manic symptoms (affects mood regulation).
- Targeting PTSD with ultramicronized palmitoylethanolamide: Results from a randomized trial integrating pharmacotherapy and cognitive behavioral therapy
PubMed ID: 41240672
Ultramicronized PEA, especially with CBT, produced large and sustained reductions in PTSD and anxiety scores, implying mood benefits.
Swelling relief (4)
- Palmitoylethanolamide Reduces Proinflammatory Markers in Unvaccinated Adults Recently Diagnosed with COVID-19: A Randomized Controlled Trial
PubMed ID: 36084236
Well‑conducted RCT in COVID reduced multiple proinflammatory biomarkers (IL‑1β, IL‑2, sP‑selectin), consistent with less inflammatory swelling.
- The Efficacy of Palmitoylethanolamide (Levagen+) on the Incidence and Symptoms of Upper Respiratory Tract Infection-A Double Blind, Randomised, Placebo-Controlled Trial
PubMed ID: 37892528
Fewer URTI episodes and reduced symptom severity imply lower local inflammatory responses in the PEA group.
- A randomized interventional clinical trial assessing the safety and effectiveness of PeaNoc XL tablets in managing joint pain and inflammation in arthritis patients
PubMed ID: 37767025
PEA+astaxanthin significantly reduced inflammatory cytokines (TNF‑α, IL‑6, IL‑1β, CRP), consistent with lowered swelling/inflammation.
- Effectiveness of a nutraceutical agent in the non-surgical periodontal therapy: a randomized, controlled clinical trial
PubMed ID: 32556659
Adjunct nutraceutical (containing PEA) reduced local periodontal inflammation and bleeding on probing.
Joint mobility (4)
- Palmitoylethanolamide and acetyl-L-carnitine act synergistically with duloxetine and pregabalin in fibromyalgia: results of a randomised controlled study
PubMed ID: 37378482
Fibromyalgia FIQR improvement includes physical function—PEA+ALC improved these composite measures.
- A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis
PubMed ID: 30927159
WOMAC function scores improved significantly in the knee OA RCT, indicating enhanced mobility.
- A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain
PubMed ID: 36057884
DPN RCT reported improved function (BPI interference), supporting improved mobility in neuropathic patients.
- A randomized interventional clinical trial assessing the safety and effectiveness of PeaNoc XL tablets in managing joint pain and inflammation in arthritis patients
PubMed ID: 37767025
PEA+astaxanthin improved WOMAC function in arthritis patients, indicating better mobility.
Stress resilience (4)
- Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial
PubMed ID: 29486338
Adjunctive PEA accelerated antidepressant response; lowering depressive symptoms likely reduces stress reactivity though not directly measured.
- Palmitoylethanolamide Reduces Proinflammatory Markers in Unvaccinated Adults Recently Diagnosed with COVID-19: A Randomized Controlled Trial
PubMed ID: 36084236
Reductions in multiple inflammatory biomarkers in COVID patients suggest a dampened systemic stress/inflammatory response.
- Targeting PTSD with ultramicronized palmitoylethanolamide: Results from a randomized trial integrating pharmacotherapy and cognitive behavioral therapy
PubMed ID: 41240672
Large, sustained reductions in PTSD and anxiety scores with ultramicronized PEA (especially +CBT) indicate strong calming of stress response.
- The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study
PubMed ID: 33070154
FAAH inhibitor increased PEA and showed secondary responder improvements in social anxiety, supporting stress reduction potential.
Relaxation (4)
- Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial
PubMed ID: 29486338
Rapid antidepressant effects with adjunctive PEA likely lead to greater subjective relaxation/anxiolysis though relaxation was not a primary endpoint.
- A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain
PubMed ID: 36057884
Improvements in sleep and mood in DPN trial are consistent with increased relaxation/less arousal.
- Targeting PTSD with ultramicronized palmitoylethanolamide: Results from a randomized trial integrating pharmacotherapy and cognitive behavioral therapy
PubMed ID: 41240672
PEA‑um combined with CBT produced large anxiety reductions, consistent with increased relaxation.
- Ultra-micronized Palmitoylethanolamide Effects on Sleep-wake Rhythm and Neuropathic Pain Phenotypes in Patients with Carpal Tunnel Syndrome: An Open-label, Randomized Controlled Study
PubMed ID: 29676237
Improved sleep and reduced pain likely contributed to greater relaxation in treated patients.
Illness recovery (3)
- Effectiveness of the association micronized N-Palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study
PubMed ID: 21601979
PEA+transpolydatin given after laparoscopy reduced pelvic pain vs placebo—supports faster postoperative symptomatic recovery.
- Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial
PubMed ID: 37380908
Large randomized trial showed substantially higher and faster olfactory recovery with um‑PEA–LUT + training.
- Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo- Controlled Clinical Trial
PubMed ID: 35450527
Large RCT showed markedly faster olfactory recovery vs control (TDI gains), indicating faster sensory recovery.
Joint comfort (3)
- Palmitoylethanolamide and acetyl-L-carnitine act synergistically with duloxetine and pregabalin in fibromyalgia: results of a randomised controlled study
PubMed ID: 37378482
Fibromyalgia FIQR improvements include stiffness domain—trial showed significant FIQR reduction with PEA+ALC.
- A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis
PubMed ID: 30927159
WOMAC improvements in knee OA likely include reduced stiffness although stiffness subscore not emphasized in the abstract.
- A randomized interventional clinical trial assessing the safety and effectiveness of PeaNoc XL tablets in managing joint pain and inflammation in arthritis patients
PubMed ID: 37767025
PEA+astaxanthin significantly improved WOMAC stiffness in arthritis patients versus baseline/standard therapy.
Focus & concentration (3)
- Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study
PubMed ID: 36010630
Nonrandomized long‑COVID study reported reduced brain‑fog scores after daily PEA‑LUT, indicating improved mental clarity.
- Formulated Palmitoylethanolamide Supplementation Improves Parameters of Cognitive Function and BDNF Levels in Young, Healthy Adults: A Randomised Cross-Over Trial
PubMed ID: 38398813
Formulated PEA (Levagen+) increased BDNF and produced modest, significant improvements in memory measures in healthy adults.
- Co-ultramicronized palmitoylethanolamide/luteolin normalizes GABA(B)-ergic activity and cortical plasticity in long COVID-19 syndrome
PubMed ID: 36455453
RCT restored GABAB inhibition and cortical plasticity in long‑COVID fatigue/cognitive complaints—neurophysiologic basis for sharper focus.
Workout performance (2)
- A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis
PubMed ID: 30927159
Reduced knee pain and improved function in OA may make exercise more comfortable.
- Effects of two different specific neck exercise interventions on palmitoylethanolamide and stearoylethanolamide concentrations in the interstitium of the trapezius muscle in women with chronic neck shoulder pain
PubMed ID: 24995488
Exercise altered local muscle PEA/SEA in chronic neck/shoulder pain and changes correlated with pain—supports a role in exercise‑related comfort.
Healthy aging (2)
- A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis
PubMed ID: 30927159
Improved pain/function in knee OA (common age‑related condition) may contribute to a healthier aging experience.
- Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram
PubMed ID: 32591562
Improved retinal ganglion function, lower IOP and vision‑related QoL in glaucoma patients supports healthier aging perception.
Sleep quality (2)
- Ultra-micronized Palmitoylethanolamide Effects on Sleep-wake Rhythm and Neuropathic Pain Phenotypes in Patients with Carpal Tunnel Syndrome: An Open-label, Randomized Controlled Study
PubMed ID: 29676237
Ultramicronized PEA produced highly significant improvement in overall sleep quality (PSQI) in carpal tunnel patients.
- A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain
PubMed ID: 36057884
Randomized trial reported improved sleep alongside pain reduction in diabetic peripheral neuropathy.
Energy & Fatigue (2)
- A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain
PubMed ID: 36057884
DPN trial reported improved function/sleep/mood which can manifest as increased energy.
- Co-ultramicronized palmitoylethanolamide/luteolin normalizes GABA(B)-ergic activity and cortical plasticity in long COVID-19 syndrome
PubMed ID: 36455453
Improvements in cortical physiology in long‑COVID patients with fatigue suggest potential for more energy.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Palmitoylethanolamide
Search all76 products whose verified label declares Palmitoylethanolamide — not every bottle that mentions it in a title.
Being studied right now
Recruiting clinical trials registered on ClinicalTrials.gov. A trial in progress has no result yet — this is what the field is asking, not what it found.